Intelligence Feed event · Capital · 2026-09-12

    Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A Pipeline

    Question

    Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A Pipeline

    Direct answer

    While Eli Lilly's valuation remains heavily anchored to its tirzepatide franchise, its immunology business reached $2.6 billion in the first half of 2026 (+9% YoY). Commercial uptake of Ebglyss (atopic dermatitis) and Omvoh (ulcerative colitis) is expanding the non-incretin revenue base. The integration of DICE, Morphic, and Merida acquisitions adds oral small-molecule integrin and IL-17 inhibitors to the pipeline, positioning Lilly to compete directly against AbbVie and Johnson & Johnson in immunology.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A Pipeline”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-h1-immunology-revenue-hits-2-6b-via-taltz-and-m-a-pipeline-a112ec

    CAPITAL
    Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A Pipeline
    While Eli Lilly's valuation remains heavily anchored to its tirzepatide franchise, its immunology business reached $2.6 billion in the first half of 2026 (+9% YoY). Commercial uptake of Ebglyss (atopic dermatitis) and Omvoh (ulcerative colitis) is expanding the non-incretin revenue base. The integration of DICE, Morphic, and Merida acquisitions adds oral small-molecule integrin and IL-17 inhibitors to the pipeline, positioning Lilly to compete directly against AbbVie and Johnson & Johnson in immunology.
    LLYABBV
    Impact
    64
    SEP 12
    SIG
    85%
    LLYABBV
    Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A Pipeline
    While Eli Lilly's valuation remains heavily anchored to its tirzepatide franchise, its immunology business reached $2.6 billion in the first half of 2026 (+9% YoY). Commercial uptake of Ebglyss (atopic dermatitis) and Omvoh (ulcerative colitis) is expanding the non-incretin revenue base. The integration of DICE, Morphic, and Merida acquisitions adds oral small-molecule integrin and IL-17 inhibitors to the pipeline, positioning Lilly to compete directly against AbbVie and Johnson & Johnson in immunology.
    → Commercial scaling of Ebglyss and Omvoh diversifies Eli Lilly's consolidated top-line beyond GLP-1 incretin dependence into high-margin autoimmune therapeutics.
    Impact
    While Eli Lilly's valuation remains heavily anchored to its tirzepatide franchise, its immunology business reached $2.6 billion in the first half of 2026 (+9% YoY). Commercial uptake of Ebglyss (atopic dermatitis) and Omvoh (ulcerative colitis) is expanding the non-incretin revenue base. The integration of DICE, Morphic, and Merida acquisitions adds oral small-molecule integrin and IL-17 inhibitors to the pipeline, positioning Lilly to compete directly against AbbVie and Johnson & Johnson in immunology.
    Affected
    LLYABBV
    Transmission
    Commercial scaling of Ebglyss and Omvoh diversifies Eli Lilly's consolidated top-line beyond GLP-1 incretin dependence into high-margin autoimmune therapeutics.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYnon-GLP-1 pharmaceutical revenue diversification and margin accretionUp1-3mImmunology revenues rose 9% YoY to $2.6B in H1 2026.
    ABBVimmunology market share competition against Skyrizi and RinvoqMixed1-3mEli Lilly's Ebglyss and Omvoh compete directly in atopic dermatitis and IBD categories.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month